The Potency of Virulent Newcastle Disease Virus Tabanan-1/ARP/2017 as Virotherapy Agents in Rat Fibrosarcoma Models

Authors

  • Palagan Senopati Sewoyo Student, Faculty of Veterinary Medicine, Udayana University, Indonesia.
  • Anak Agung Ayu Mirah Adi Laboratory of Veterinary Pathology, Faculty of Veterinary Medicine, Udayana University, Indonesia.
  • Ida Bagus Oka Winaya Laboratory of Veterinary Pathology, Faculty of Veterinary Medicine, Udayana University, Indonesia.
  • I Putu Sampurna Laboratory of Biostatistics, Faculty of Veterinary Medicine, Udayana University, Indonesia.
  • Anak Agung Bagus Bramardipa Student, Faculty of Medicine and Health Sciences, Udayana University, Jln. P.B. Sudirman, Denpasar, Bali, Indonesia.

Abstract

Newcastle Disease Virus (NDV) has oncolytic activity and has been promoting as a virotherapy agent.  The objective of this study was to evaluate the potency of NDV Tabanan-1/ARP/2017 as a virotherapy agent. This study was used the white rat Rattus norvegicus as an animal fibrosarcoma model. Benzo(a)pyrene solution at 0.3% (w/v) was used to induce fibrosarcoma. After fibrosarcoma appeared, rats were treated as follows: Rats in group P0 were injected with 0.5 mL phosphate buffer saline (PBS), while those in group P1 were injected with the ND virus, intratumorally at a dose of 0.5 mL of 29 HA titer of NDV Tabanan-1/ARP/2017. The dynamic of tumor growth was evaluated. Upon the starting point of the treatment, the mean volume of rat tumors mass of P0 and P1 were 1,769.83±1,103.58 mm3 and 1,194.29±592.82 mm3, respectively. At the end of the treatment, the mean tumor volume of P0 was 8,549.38±5,347.51 mm3, while at P1 was 3,848.25 ± 3,539,189 mm3. From the observation of microscopic images, it was found that the number of blood vessels at P1 was 44.67±19.348, significantly lower (p<0.05) than that of the P0 (121.33±34.530). From this study, it can be concluded that virotherapy with NDV-Tabanan-1/ARP/2017, can inhibit fibrosarcoma growth and reduce the number of blood vessel in the tumor. The effectiveness of Tabanan-1/ARP/2017 as a virotherapy agent is discussed.

Downloads

Published

2021-04-01

How to Cite

Sewoyo, P. S., Adi, A. A. A. M., Winaya, I. B. O. ., Sampurna, I. P., & Bramardipa, A. A. B. (2021). The Potency of Virulent Newcastle Disease Virus Tabanan-1/ARP/2017 as Virotherapy Agents in Rat Fibrosarcoma Models. Journal of Advanced Veterinary Research, 11(2), 64-68. Retrieved from https://advetresearch.com/index.php/AVR/article/view/643

Issue

Section

Original Research